Inclusion Criteria:

          -  Aged more than 3 years up to the 18th birthday

          -  Radiological diagnosis of DIPG with tumor confined to the region of the pons or

          -  thalami without cystic changes or hematoma obstructing the planned catheter
             trajectories

          -  Radiological diagnosis of thalamic gliomas confined to bilateral thalami without
             cystic changes or hematoma obstructing the planned catheter trajectories

          -  Radiological features of DIPG: intrinsic, pontine based infiltrative lesion;
             hypointense in T1 weighted images (T1WIs) and hyperintense in T2 sequences, with mass
             effect on the adjacent structures and occupying at least 50% of the pons

          -  No prior therapy is allowed other than involved field radiotherapy (54Gy) and
             cerebrospinal fluid (CSF) diversion for hydrocephalus, including endoscopic third
             ventriculostomy (ETV) or a ventriculo-peritoneal shunt. No concomitant medicine or
             therapies for treatment are permitted while the patient is enrolled in this study.

          -  Karnofsky performance status or Lansky play score of ≥70 assessed at diagnosis

          -  Total bilirubin: within normal institutional limits

          -  Aspartate Aminotransferase (AST)(SGOT)/Alanine Aminotransferase (ALT)(SGPT): ≤ 2.5 ×
             institutional upper limit of normal (ULN)

          -  Creatinine: within normal institutional limits

          -  Creatinine clearance: ≥ 60 mL/min/1.73m2 for patients with creatinine levels above
             institutional normal

          -  Absolute neutrophil count: ≥ 1,500/μL

          -  Platelet count: ≥ 100,000/μL - no transfusion within 7 days

          -  Hemoglobin level: ≥ 10g/dL - no transfusion within 7 days

          -  Partial Thromboplastin Time (PT) and activated partial thromboplastin time (APTT):
             within normal institutional limits

          -  No documented current bleeding disorder

          -  No medical condition that would preclude general anesthesia

          -  No severe acute infection or unexplained febrile illness

          -  Not pregnant or nursing - negative serum pregnancy test if appropriate within 7 days
             of study entry (adequate contraceptive methods for females and males required)

          -  No documented allergy to compounds of similar chemical or biologic composition to
             MTX110 or gadolinium compounds

          -  Subjects with a history of seizures/epilepsy should be on anticonvulsant medication
             prior to the first operative procedure on study, with serum levels within a
             therapeutic range

          -  Subjects must be able to undergo MR-imaging with gadolinium-based contrast
             administration (e.g. no ferrous-containing implants, no pacemakers, etc.)

          -  All subjects or their legal guardians must sign a document of informed consent
             indicating their understanding of the investigational nature and the potential risks
             associated with this study. When appropriate, pediatric subjects will be included in
             all discussions in order to obtain verbal and written assent

        Exclusion Criteria:

          -  Radiological evidence of distant disease outside the pons or thalami

          -  Radiological evidence of metastatic disease within the central nervous system (CNS) at
             diagnosis

          -  Subjects with an uncorrectable bleeding disorder

          -  Subjects with multifocal or leptomeningeal disease beyond the pons or the thalami

          -  Subjects with signs of impending herniation or an acute intratumoral hemorrhage

          -  Subjects that have received or are on concurrent chemotherapy or biologic therapy for
             the treatment of their tumor

          -  Subjects who are pregnant or breastfeeding

          -  Previous experimental or trial-based therapy

          -  Patients who are known human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C
             positive. HIV-positive patients on combination antiretroviral therapy are ineligible
             because of the potential for pharmacokinetic interactions with MTX110.

          -  Patients with systemic diseases which may be associated with unacceptable
             anesthetic/operative risk